In the pivotal GRID trial, STIVARGA demonstrated statistically significant improvement in PFS in previously treated patients with GIST1,2
STIVARGA was studied in patients with a high unmet need following disease progression on 2 prior TKIs in GRID1
Patient population with a high unmet need following the failure of 2 prior TKIs. Demographics were similar between arms.1
GRID patient population1
STIVARGA (n=133) | Placebo (n=66) | |
---|---|---|
Median age, y | 60 | 61 |
Sex | ||
Male | 64% | 64% |
Female | 36% | 36% |
Ethnic group | ||
White | 68% | 68% |
Black or African American | 0% | 2% |
Asian | 26% | 24% |
Not reported or missing | 7% | 6% |
Performance status | ||
ECOG 0 | 55% | 56% |
ECOG 1 | 45% | 44% |